The complaint filed against the NASDAQ-listed company claims management violated the Securities Exchange Act of 1934 by disseminating false information. According to the court filing, GRAIL repeatedly touted the progress of the NHS-Galleri trial while withholding critical, adverse findings from the public. These omissions allegedly rendered the company’s market statements materially misleading throughout the specified class period.
Investors Target GRAIL, Inc. in Securities Fraud Class Action
Investors who held GRAIL, Inc. stock between May 13, 2025, and February 19, 2026, face an August 4, 2026, deadline to join a class action lawsuit. The litigation alleges the biotech firm misled shareholders regarding the clinical trial results of its flagship NHS-Galleri test.
The DJS Law Group is currently organizing the litigation, inviting shareholders who sustained losses to participate in the recovery effort. While the firm is seeking candidates for lead plaintiff appointments, individual investors are not required to hold that title to remain eligible for potential compensation. Interested parties may contact David J. Schwartz at the firm’s Eastchester, New York office to discuss their legal standing before the upcoming August deadline.
Comments (0)
No comments yet. Be the first!